Despite a bevy of options to manage atrial fibrillation, many questions remain unanswered regarding the utility of monitoring and anticoagulation.
Existing literature is compelling enough to warrant further studies to determine the safety, efficacy, and benefits of cannabinoids.
One expert explains why Alzheimer’s research and therapeutics are poised for major gains over the next decade.
An investigational BACE inhibitor for the treatment of early Alzheimer’s disease is moving into Phase 3 trials, following confirmation from the FDA. Developed in a partn… read more
The FDA has approved Zinbryta (daclizumab, Biogen/AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS). The … read more
NFL player Eugene Monroe has donated $80,000 to researchers at Johns Hopkins University and the University of Pennsylvania to examine the therapeutic potential of cannabinoid … read more
The FDA has approved Nuplazid (pimavanserin) from Acadia Pharmaceuticals for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, whi… read more